研发产品线

1.开发阶段和地域

地域 临床試験
3期
申請中 认可
日本

SJP-0133
<Wet AMD>

brimonidine/brinzolamide
<Glaucoma,OH>

海外

SJP-0035
<Dry eye>
United States

   

2.产品信息

药品剂型特性适应证
brimonidine/brinzolamide Topical ophthalmic solution Combination ophthalmic solution Glaucoma,
Ocular hypertension
SJP-0035 Topical ophthalmic solution Novel mechanism of action Dry eye
SJP-0133 Injection Biosimilar of Ranibizumab Wet AMD

3.其他信息

brimonidine/brinzolamideIt is a fixed combination ophthalmic solution that comprised of brimonidine, which is the α2 agonist, and brinzolamide, which is the carbonic anhydrase inhibitor.